Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Assets (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Other Non-Current Assets data on record, last reported at $12.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2727.76% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, up 2727.76%, while the annual FY2025 figure was $12.0 million, 2727.76% up from the prior year.
  • Other Non-Current Assets reached $12.0 million in Q4 2025 per MIRM's latest filing, up from $480000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $12.0 million in Q4 2025 and bottomed at $250000.0 in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $2.2 million, with a median of $1.5 million recorded in 2021.
  • The widest YoY moves for Other Non-Current Assets: up 2727.76% in 2025, down 91.08% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2021, then fell by 22.62% to $1.4 million in 2022, then surged by 201.37% to $4.2 million in 2023, then plummeted by 89.8% to $425000.0 in 2024, then soared by 2727.76% to $12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $12.0 million in Q4 2025, $480000.0 in Q3 2025, and $480000.0 in Q2 2025.